Venture Investors

What three companies’ decisions to delist say about life on the London exchange for development-stage biotechs

Plus deals for GenEdit, Elephas and more

Plus: Immunic eyes $240M private placement and updates from Applied Therapeutics and Novartis  

Novo tops list with 43 investments in European biotechs

Bank acted as administrator plus loan provider to help high-risk companies receive ‘small’ amounts of money

Just 10 VCs have populated the annual top-five list over the past five years

What we promised 30 years ago still holds true, even as our scope and global reach have grown: BioCentury’s 30th anniversary collection

11 VCs have dominated the top 5 chart over the past five years, with RA Capital again leading this year

Firm’s model attracts top academics for company creation 

Omega Fund head discusses disengagement with Russia, IPOs in a down-market, and concerns about salary and title inflation